Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients

Abstract

Background: Colorectal cancer (CRC) is one of the most frequent cancers. Genetic mutations in CRC already described can be detected in feces. Microarray methods in feces can represent a new diagnostic tool for CRC and significant improvement at public health. Aim: to analyze stool DNA by human DNA quantify and microarray methods as alternatives to CRC screening. Method: Three methods were analyzed in stool samples: Human DNA Quantify, RanplexCRC and KRAS/BRAF/PIK3CA (KBP) Arrays. Results: KBP array mutations were presented in 60.7% of CRC patients and RanplexCRC Array mutations in 61.1% of CRC patients. Sensitivity and specificity for human DNA quantification was 66% and 82% respectively. Fecal KBP Array had 35% sensitivity and 96% specificity and RanplexCRC Array method had 78% sensitivity and 100% specificity. Conclusion: Microarray methods showed promise as potential biomarkers for CRC screening; however, these methods had to be optimized to improve accuracy and applicability by clinical routine.

KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature

“…Molecules and genes in these pathways at different phases have been shown as targets in cancer pathogenesis. In this context, mutations of the BRAF, KRAS, and PIK3CA genes were identified with varying frequencies in many cancer types [2][3][4][5][6][7][8][9][10]. BRAF and PI3K inhibitors have taken place in treatment schemes at various stages; studies for KRAS still continue at changing clinical and laboratory stages [11][12][13].…”